Predictive signature of response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer cells by tyrosine kinase activity profiling

被引：0
|
作者：
Izawa, Naoki [1 ]
Serizawa, Masakuni [1 ]
Naji, Faris [2 ]
de Wijn, Rik [2 ]
Hilhorst, Riet [2 ]
Ruijtenbeek, Rob [2 ]
Yasui, Hirofumi [3 ]
Nakajima, Takako [4 ]
Boku, Narikazu [4 ]
Koh, Yasuhiro [1 ]
机构：
[1] Shizuoka Canc Ctr, Drug Discovery & Dev Div, Shizuoka, Japan
[2] Pamgene Int BV, Shertogenbosch, Netherlands
[3] Shizuoka Canc Ctr, Gastrointestinal Div, Shizuoka, Japan
[4] St Marianna Univ, Sch Med, Clin Oncol Div, Kawasaki, Kanagawa, Japan
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-4248
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4248
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Yao, Yu
    Yang, Huaping
    Zhu, Bo
    Wang, Song
    Pang, Jiaohui
    Wu, Xiaoying
    Xu, Yang
    Zhang, Junli
    Zhang, Jinfeng
    Ou, Qiuxiang
    Tian, Hui
    Zhao, Zheng
    [J]. RESPIRATORY RESEARCH, 2023, 24 (01)
  • [2] Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
    Yu Yao
    Huaping Yang
    Bo Zhu
    Song Wang
    Jiaohui Pang
    Xiaoying Wu
    Yang Xu
    Junli Zhang
    Jinfeng Zhang
    Qiuxiang Ou
    Hui Tian
    Zheng Zhao
    [J]. Respiratory Research, 24
  • [3] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A. F.
    [J]. ONCOGENE, 2009, 28 : S24 - S31
  • [4] Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    A F Gazdar
    [J]. Oncogene, 2009, 28 : S24 - S31
  • [5] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [6] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    [J]. Current Treatment Options in Oncology, 2016, 17
  • [7] Pyrimidine derivatives as EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: A comprehensive review
    Kizhakkedath Ratheesh, Anandu
    Pottankottu Jayan, Ajay
    Presanna, Aneesh Thankappan
    Nirmala, Saiprabha Vijayakumar
    [J]. CHEMICAL BIOLOGY & DRUG DESIGN, 2022, 100 (04) : 599 - 621
  • [8] Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives
    Kim, Toe-You
    Han, Soe-Won
    Bang, Yung-Jue
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2007, 7 (06) : 821 - 836
  • [9] Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
    Murray, Samuel
    Karavasilis, Vasilios
    Bobos, Mattheos
    Razis, Evangelia
    Papadopoulos, Savvas
    Christodoulou, Christos
    Kosmidis, Paris
    Fountzilas, George
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2012, 31
  • [10] Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
    Samuel Murray
    Vasilios Karavasilis
    Mattheos Bobos
    Evangelia Razis
    Savvas Papadopoulos
    Christos Christodoulou
    Paris Kosmidis
    George Fountzilas
    [J]. Journal of Experimental & Clinical Cancer Research, 31
12345